Table 2. Response to treatment.
| Best overall response–no. (%) | Pembrolizumab, N=26 (65%) Nivolumab, N=14 (35%) | Ipilimumab, N=40 |
|---|---|---|
| Complete response | 0 | 0 |
| Partial response | 8 (20) | 4 (10) |
| Stable disease | 15 (38) | 3 (8) |
| Progressive disease | 17 (42) | 33 (82) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.